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Purpose/Objective: To assess acute and late toxicities and 
report the frequency and timing of the PSA bounce in 
intermediate-risk prostate cancer patients treated with 
brachytherapy and hypofractionated external beam 
radiotherapy (EBRT) combined with short course androgen 
deprivation therapy (ADT). 
Materials and Methods: Between August 2003 and September 
2007, 51 patients with intermediate-risk prostate cancer 
were enrolled in a dose escalation phase II protocol (BRP-1 
trial). The treatment regimen applied was as followed: 
patients received six months of ADT (three months 
neoadjuvantly and three months concurrently) and 
underwent high-dose-rate (HDR) Ir192 prostate brachytherapy, 
for a prescribed dose of 19.5Gy (three fractions of 6.5Gy 
each); followed one week later, by hypofractionated EBRT at 
a dose of 50Gy in 20 fractions. Patients were assessed one 
month post-treatment, every three to six months for the first 
five years and annually thereafter. APS, testosterone and 
complete blood count were taken on each visit. 
Gastrointestinal (GI), genitourinary (GU) and sexual toxicities 
were assessed according to the RTOG toxicity scoring 
criteria. Patients also completed the Expanded Prostate 
Cancer Index Composite (EPIC) questionnaires for quality of 
life every 6 months. 
Results: Median age was 68.5 years (range 51-83 years). At 
diagnosis, 31.8% of patients had grade 2 or higher for GU 
symptoms according to the RTOG scoring criteria, no one had 
grade 2 GI symptoms and 50% had grade 2 or higher erectile 
dysfunction. Median follow-up was 80 months (range 4.9-132 
months). Rates of grade 2 and higher GU toxicity at 1, 12 and 
60 months were 33.8%, 12.8% and 23.5%, respectively. No 
grade 2 or higher GI toxicities were reported at 1 and 12 
months and a rate of 5.9% was observed at 60 months. Grade 
2 and 3 erectile dysfunction at 1, 12 and 60 months was 
reported in 2.1%, 19.2% and 16.1% and 91.7%, 57.2% and 71% 
of patients respectively. No grade 4 toxicity was reported. 
PSA bounce was observed in 33.3% of patients at a median of 
12 months (range 3-42 months) and the median time to PSA 
normalization was 18 months (range 3-24 months).  
Conclusions: Acute and late GU and GI toxicities were 
acceptable for patients with intermediate-risk prostate 
cancer treated with HDR brachytherapy and hypofractionated 
EBRT combined to short course ADT. Rates of erectile 
dysfunction were probably affected by the use of a short 
course of ADT. PSA bounces are common, and occur up to 42 
months in our cohort. 
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Purpose/Objective: Low dose rate (LDR) brachytherapy is 
accepted as a treatment option for low risk prostate cancer 
producing excellent long term outcomes. The GEC-ESTRO 
guidelines recommend a 100% isodose prescription of 145Gy 
for Iodine-125 implantable seeds. In our practice we 
prescribe to 160Gy to low and intermediate risk cases, as 
increasing dose has been associated with improved outcomes. 
We analysed our implant and post-implant dosimetric 
parameters, relative to the current GEC-ESTRO guidelines.  
Materials and Methods: A single operator cohort of patients 
was selected to control inter-operator variability. Data for 
patients in our Trust is prospectively collected and compiled 
into the ProBrachy European and Royal Berkshire local 
database. Median values were used to assess the 
performance of the cohort. Statistical analysis was performed 
on SPSS v22. 
Results: 
 
 
A total of 95 patients treated with low dose rate 
brachytherapy were identified. Patient characteristics and 
tumour stage are summarised below. Median prostate volume 
implanted was 35.81cc (Range 18.3-83.8cc). Pre-implant 
ultrasound volume assessments showed excellent correlation 
with the implant ultrasound volumes and post implant CT 
(Pearson’s r = 0.926 and 0.93, respectively).  
 
GEC-
ESTRO 
145Gy  160Gy Implant  
(median) 
Post 
Implant  
(median) 
V100 (CTV) ≥95% - - 98% 95% 
D90 (CTV) ≥100%  145Gy 160Gy 186.99 
Gy 
175.5 Gy 
V150 (CTV) ≤50% - - 54% 53% 
D2cc 
Rectum 
≤145Gy 145Gy 160Gy 94.425 
Gy 
72.5 Gy 
D10 Urethra ≤150%  217.5 
Gy 
240 
Gy 
202.83 
Gy 
214.59 Gy 
D30 Urethra ≤130%  188.5 
Gy 
208 
Gy 
193.7Gy  199.27 Gy 
 
